Across TCGA pan-cancer cohorts, CXCL11 Mutation is linked to patient survival in 1 of 34 cancer types, making it a survival-associated CXCL11 data layer compared with 24 for mass-spec protein.
The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where higher CXCL11 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated CXCL11 expression acts as an unfavorable survival marker.
KIRC are the cancer types where CXCL11 Mutation most reproducibly stratifies survival.